Physician
Nuclear Medicine
Dr. Sally J. Denardo, MD
|
|
Give Review
Sally J. Denardo, MD is an expert in the field of Nuclear Medicine. She graduated from University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine Sally J. Denardo is also a published doctor. She has 54 paper published. The most recent paper is: In-Vivo Biodistribution and Safety of (99m)Tc-LLP2A-HYNIC in Canine Non-Hodgkin Lymphoma.
Publications
- In-Vivo Biodistribution and Safety of (99m)Tc-LLP2A-HYNIC in Canine Non-Hodgkin Lymphoma.
- Concepts, consequences, and implications of theranosis.
- A general chemical synthesis platform for crosslinking multivalent single chain variable fragments.
- Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas.
- Health care in the United States in 2009: both sides of the "counter".
- 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
- Update: Turning the heat on cancer.
- Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.
- Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
- Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells.
- Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.
- Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia.
- Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
- Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
- Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.
- Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues.
- Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.
- Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
- Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
- Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
- Recombinant antibodies: from the laboratory to the clinic.
- Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging.
- Cure of incurable lymphoma.
- Targeted radionuclide therapy for solid tumors: an overview.
- Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
- Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft.
- Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds.
- Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
- Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
- Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer.
- Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
- High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to in...
- Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
- Radioimmunodetection and therapy of breast cancer.
- Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
- Radiometals as payloads for radioimmunotherapy for lymphoma.
- Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
- Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.
- Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
- Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.
- Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.
- Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N...
- Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?
- Characterization of human IgG antimouse antibody in patients with B-cell malignancies.
- Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
- Components of professional competence for nuclear medicine physicians.
- Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
- Treatment planning for molecular targeted radionuclide therapy.
- Choosing an optimal radioimmunotherapy dose for clinical response.
- Combined modality radioimmunotherapy. Promise and peril.
- Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
- Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
- Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
Schools
Center Of Chicago Pritzker School Of Medicine
Stanford Med Center
Doctors Specialties
- Nuclear Medicine
Accepted Insurances
Education
-
Stanford University -
University of Chicago Pritzker School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. William R. Kimball, MD |
|
|
Dr. Vicki E. Nagano, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eugenio Gerscovich, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Erno J. Gyetvai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Konrad, MD |
|
|
Dr. Philip Matin, MD |
|
|
Dr. Nhan T. Nguyen, MD |
|
|
Dr. Don N. Udall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elma F. Abella, MD |
|
|
Dr. Marie R. Carlisle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen W. Kennedy, MD |